Plus: Candid joining two VC-backed start-ups to focus on autoimmune bispecifics, and updates from Eli Lilly, Haya, Genetic Leap and more 

Fewer rounds by preclinical companies a drag on series A financings

Plus Northern Gritstone raises $268M, and updates from Athersys, Zymeworks, Foghorn and more

Pharma views Acceleron’s sotatercept as growth driver following Keytruda patent expiration

Plus: Vedanta, bluebird, Cytokinetics and more

Partners AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) said HER2-targeted antibody-drug conjugate (ADC) Enhertu fam-trastuzumab deruxtecan-nxki received two additional

Drug development for heart failure is picking up, with five clinical readouts from five mechansims expected in the next year